Boehringer Ingelheim extends “one-stop-shop” service with new Fill & Finish capabilities in China
July 4th 2018
- Isolator based fill & finish line in full GMP operations
- State-of-the-art technology for local and global customers in contract manufacturing business of Boehringer Ingelheim
- Manufacturing of drug substance and drug product all under one roof at OASIS, Shanghai
Shanghai, China July 4, 2018 - Boehringer Ingelheim, a leading contract manufacturer for biopharmaceutical medicines, has rounded off its full-service capabilities for customers with a new filling line at Shanghai, China. With this latest extension the contract manufacturing business Boehringer Ingelheim BioXcellence™ now offers manufacturing of drug substance, drug product and all corresponding quality control and assurance activities to their customers under one roof at its commercial manufacturing facility OASIS in Shanghai. The new isolator based fill & finish line is in full GMP operations for aseptic filling of liquids in vials.
Fill & finish as the final manufacturing step is critical to ensure the safety and efficacy of a biopharmaceutical medicine. Under aseptic conditions the drug substance is filled into containers before labelling and packaging as final drug product. The new line with isolator technique represents one further step in Boehringer Ingelheim's one stop shop for contract development and manufacturing of biopharmaceuticals at its site in Shanghai. With this state-of–the-art technology Boehringer Ingelheim BioChina offers further excellence and solutions in the contract manufacturing business to its local and global customers.
”I believe that our customers will benefit from this investment by receiving high quality drug substance and drug product from one source as a convenient pathway to deliver biopharmaceuticals to our customers and, in the end, to patients”, stated Dr. Luo Jiali, General Manager of Boehringer Ingelheim Biopharmaceuticals (China) Co Ltd.
Boehringer Ingelheim BioXcellence™
Boehringer Ingelheim is one of the world’s largest manufacturers of biopharmaceuticals. With over 35 years of experience in this field, the company is an industry pioneer and has produced more than 25 biopharmaceuticals for global markets. Represented by the brand Boehringer Ingelheim BioXcellence™, it offers tailor-made contract development and manufacturing services to the industry, providing the entire production technology chain from DNA to fill and finish through its network in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ secures supply throughout the entire product lifecycle — transferring customer projects at any stage, delivering to almost any scale and thereby making outsourcing easy.
Boehringer Ingelheim China
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim Germany, the company operates presently with a total of some 50,000 employees. Boehringer Ingelheim entered into the Chinese market in 1994, headquartered in Shanghai with more than 3500 employees. The major business focuses of BI China include human pharma, animal health and biopharmaceuticals. In recent years, BI has achieved continuous growth, outperformed the market average. BI has been certified as “China Top Employer” during 2014 to 2018. To become the premier multinational pharmaceutical company is the vision of Boehringer Ingelheim China. The company aims to bring more and better innovative products earlier to patients to enhance their health and life quality.
As one of the world’s largest biopharmaceutical producers, Boehringer Ingelheim is China’s first international provider of biopharmaceutical contract manufacturing solutions with all-round services, including process development, clinical trials and product supply, to its clients in China and all over the world. Boehringer Ingelheim China Biopharmaceuticals Site was officially put into operation in May 2017. As the first and only biopharmaceuticals site in line with global standards set by a multinational pharma company in China, the site has become a major milestone in Boehringer Ingelheim’s strategic blueprint for its biopharmaceuticals business globally. The first-phase investment has exceeded 70 million euros.
For more information please visit www.bioxcellence.com.